NMDA receptor subunits and associated signaling molecules mediating antidepressant-related effects of NMDA-GluN2B antagonism

Behavioural Brain Research

Volumn 287, Issue , 2015, Pages 89-95

  Kiselycznyk, Carly ^a   Jury, Nicholas J ^a   Halladay, Lindsay R ^a   Nakazawa, Kazu ^b   Mishina, Masayoshi ^c   Sprengel, Rolf ^d   Grant, Seth G N ^e   Svenningsson, Per ^f   Holmes, Andrew ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c RITSUMEIKAN UNIVERSITY   (Japan)

^d MAX PLANCK INSTITUTE FOR MEDICAL RESEARCH   (Germany)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Depression; GluA1; GluN2B; Glutamate; Prefrontal cortex; PSD 95

Indexed keywords

4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; GLUTAMATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; POSTSYNAPTIC DENSITY PROTEIN 95; AMINO ACID RECEPTOR BLOCKING AGENT; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; DLGH4 PROTEIN, MOUSE; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 1; GPRIN1 PROTEIN, MOUSE; GUANYLATE KINASE; MEMBRANE PROTEIN; N-METHYL D-ASPARTATE RECEPTOR SUBTYPE 2A; NERVE PROTEIN; NR2B NMDA RECEPTOR; PHENOL DERIVATIVE; PIPERIDINE DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; BASOLATERAL AMYGDALA; CONTROLLED STUDY; DEPRESSION; DRUG ANTAGONISM; DRUG PROTEIN BINDING; FORCED SWIM TEST; GENE DELETION; IMMOBILITY; LOSS OF FUNCTION MUTATION; MALE; MOUSE; NONHUMAN; OPEN FIELD TEST; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN TARGETING; AMYGDALA; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DEPRESSIVE DISORDER; DRUG EFFECTS; GENETICS; INTERNEURON; KNOCKOUT MOUSE; METABOLISM;

AMYGDALA; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; EXCITATORY AMINO ACID ANTAGONISTS; GUANYLATE KINASES; INTERNEURONS; MALE; MEMBRANE PROTEINS; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; PHENOLS; PIPERIDINES; PREFRONTAL CORTEX; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84926305080     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.03.023     Document Type: Article

References (58)

1. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008, 7:426-437.
2. Yilmaz A., Schulz D., Aksoy A., Canbeyli R. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav 2002, 71:341-344.
3. Akinfiresoye L., Tizabi Y. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology (Berl) 2013, 230:291-298.
4. Autry A.E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P.F., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011, 475:91-95.
5. Gigliucci V., O'Dowd G., Casey S., Egan D., Gibney S., Harkin A. Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism. Psychopharmacology (Berl) 2013, 228:157-166.
6. Koike H., Iijima M., Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 2011, 224:107-111.
7. Maeng S., Zarate C.A., Du J., Schloesser R.J., McCammon J., Chen G., et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008, 63:349-352.
8. Parise E.M., Alcantara L.F., Warren B.L., Wright K.N., Hadad R., Sial O.K., et al. Repeated ketamine exposure induces an enduring resilient phenotype in adolescent and adult rats. Biol Psychiatry 2013, 74:750-759.
9. Li N., Liu R.J., Dwyer J.M., Banasr M., Lee B., Son H., et al. Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 2011, 69:754-761.
10. Liu R.J., Lee F.S., Li X.Y., Bambico F., Duman R.S., Aghajanian G.K. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry 2012, 71:996-1005.
11. Liu R.J., Fuchikami M., Dwyer J.M., Lepack A.E., Duman R.S., Aghajanian G.K. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology 2013, 38:2268-2277.
12. Bechtholt-Gompf A.J., Smith K.L., John C.S., Kang H.H., Carlezon W.A., Cohen B.M., et al. CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy. Psychopharmacology (Berl) 2011, 215:689-695.
13. Miller O.H., Yang L., Wang C.C., Hargroder E.A., Zhang Y., Delpire E., et al. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. Elife 2014, 3.
14. Chowdhury G.M., Behar K.L., Cho W., Thomas M.A., Rothman D.L., Sanacora G. (1)H-[(1)(3)C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism. Biol Psychiatry 2012, 71:1022-1025.
15. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997, 17:2921-2927.
16. Homayoun H., Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007, 27:11496-11500.
17. Billingslea E.N., Tatard-Leitman V.M., Anguiano J., Jutzeler C.R., Suh J., Saunders J.A., et al. Parvalbumin cell ablation of NMDA-R1 causes increased resting network excitability with associated social and self-care deficits. Neuropsychopharmacology 2014, 39:1603-1613.
18. Boyce-Rustay J.M., Holmes A. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology 2006, 31:2405-2414.
19. Brown D.G., Maier D.L., Sylvester M.A., Hoerter T.N., Menhaji-Klotz E., Lasota C.C., et al. 2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity. Bioorg Med Chem Lett 2011, 21:3399-3403.
20. Kiselycznyk C., Svenningsson P., Delpire E., Holmes A. Genetic, pharmacological and lesion analyses reveal a selective role for corticohippocampal GLUN2B in a novel repeated swim stress paradigm. Neuroscience 2011, 193:259-268.
21. Lima-Ojeda J.M., Vogt M.A., Pfeiffer N., Dormann C., Kohr G., Sprengel R., et al. Pharmacological blockade of GluN2B-containing NMDA receptors induces antidepressant-like effects lacking psychotomimetic action and neurotoxicity in the perinatal and adult rodent brain. Prog Neuropsychopharmacol Biol Psychiatry 2013, 45:28-33.
22. Poleszak E., Wosko S., Serefko A., Szopa A., Wlaz A., Szewczyk B., et al. Effects of ifenprodil on the antidepressant-like activity of NMDA ligands in the forced swim test in mice. Prog Neuropsychopharmacol Biol Psychiatry 2013, 46:29-35.
23. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
24. Preskorn S.H., Baker B., Kolluri S., Menniti F.S., Krams M., Landen J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008, 28:631-637.
25. Pozzi L., Dorocic I.P., Wang X., Carlen M., Meletis K. Mice lacking NMDA receptors in parvalbumin neurons display normal depression-related behavior and response to antidepressant action of NMDAR antagonists. PLOS ONE 2014, 9:e83879.
26. Belforte J.E., Zsiros V., Sklar E.R., Jiang Z., Yu G., Li Y., et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 2010, 13:76-83.
27. Tizabi Y., Bhatti B.H., Manaye K.F., Das J.R., Akinfiresoye L. Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats. Neuroscience 2013, 213:72-80.
28. Duman R.S., Aghajanian G.K. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012, 338:68-72.
29. Fitzgerald P.J., Barkus C., Feyder M., Wiedholz L.M., Chen Y.C., Karlsson R.M., et al. Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder?. Neurobiol Dis 2010, 40:608-621.
30. Freudenberg F., Marx V., Mack V., Layer L.E., Klugmann M., Seeburg P.H., et al. GluA1 and its PDZ-interaction: a role in experience-dependent behavioral plasticity in the forced swim test. Neurobiol Dis 2013, 52:160-167.
31. Walker A.K., Budac D.P., Bisulco S., Lee A.W., Smith R.A., Beenders B., et al. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology 2013, 38:1609-1616.
32. Cryan J.F., Holmes A. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 2005, 4:775-790.
33. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
34. Brigman J.L., Feyder M., Saksida L.M., Bussey T.J., Mishina M., Holmes A. Impaired discrimination learning in mice lacking the NMDA receptor NR2A subunit. Learn Mem 2008, 15:50-54.
35. Debrouse L., Hurd B., Kiselycznyk C., Plitt A., Todaro A., Mishina M., et al. Probing the modulation of acute ethanol intoxication by pharmacological manipulation of the NMDAR Glycine co-agonist site. Alcohol Clin Exp Res 2013, 37:223-233.
36. Mozhui K., Karlsson R.M., Kash T.L., Ihne J., Norcross M., Patel S., et al. Strain differences in stress responsivity are associated with divergent amygdala gene expression and glutamate-mediated neuronal excitability. J Neurosci 2010, 30:5357-5367.
37. Sakimura K., Kutsuwada T., Ito I., Manabe T., Takayama C., Kushiya E., et al. Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor epsilon 1 subunit. Nature 1995, 373:151-155.
38. Palachick B., Chen Y.C., Enoch A.J., Karlsson R.M., Mishina M., Holmes A. Role of major NMDA or AMPA receptor subunits in MK-801 potentiation of ethanol intoxication. Alcohol Clin Exp Res 2008, 32:1479-1492.
39. Barkus C., Feyder M., Graybeal C., Wright T., Wiedholz L., Izquierdo A., et al. Do GluA1 knockout mice exhibit behavioral abnormalities relevant to the negative or cognitive symptoms of schizophrenia and schizoaffective disorder?. Neuropharmacology 2012, 62:1263-1272.
40. Feyder M., Wiedholz L., Sprengel R., Holmes A. Impaired associative fear learning in mice with complete loss or haploinsufficiency of AMPA GluR1 receptors. Front Behav Neurosci 2007, 1:4.
41. Wiedholz L.M., Owens W.A., Horton R.E., Feyder M., Karlsson R.M., Hefner K., et al. Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and 'schizophrenia-related' behaviors. Mol Psychiatry 2008, 13:631-640.
42. Zamanillo D., Sprengel R., Hvalby O., Jensen V., Burnashev N., Rozov A., et al. Importance of AMPA receptors for hippocampal synaptic plasticity but not for spatial learning. Science 1999, 284:1805-1811.
43. Camp M.C., Feyder M., Ihne J., Palachick B., Hurd B., Karlsson R.M., et al. A novel role for PSD-95 in mediating ethanol intoxication, drinking and place preference. Addict Biol 2011, 16:428-439.
44. Daut R.A., Busch E.F., Ihne J., Fisher D., Mishina M., Grant S.G., et al. Tolerance to ethanol intoxication after chronic ethanol: role of GluN2A and PSD-95. Addict Biol 2014, 20:259-262.
45. Fitzgerald P.F., Pinard C.R., Camp M.C., Feyder M., Sah A., Bergstrom H.C., et al. Durable fear memories require PSD-95. Mol Psychiatry 2014, (in press).
46. Yang R.J., Mozhui K., Karlsson R.M., Cameron H.A., Williams R.W., Holmes A. Variation in mouse basolateral amygdala volume is associated with differences in stress reactivity and fear learning. Neuropsychopharmacology 2008, 33:2595-2604.
47. Karlsson R.M., Choe J.S., Cameron H.A., Thorsell A., Crawley J.N., Holmes A., et al. The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice. Psychopharmacology (Berl) 2008, 195:547-557.
48. Graybeal C., Feyder M., Schulman E., Saksida L.M., Bussey T.J., Brigman J.L., et al. Paradoxical reversal learning enhancement by stress or prefrontal cortical damage: rescue with BDNF. Nat Neurosci 2011, 14:1507-1509.
49. Holmes A., Fitzgerald P.J., Macpherson K.P., Debrouse L., Colacicco G., Flynn S.M., et al. Chronic alcohol remodels prefrontal neurons and disrupts NMDAR-mediated fear extinction encoding. Nat Neurosci 2012, 15:1359-1361.
50. Gunduz-Cinar O., Macpherson K.P., Cinar R., Gamble-George J., Sugden K., Williams B., et al. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry 2013, 18:813-823.
51. Zhao M.G., Toyoda H., Lee Y.S., Wu L.J., Ko S.W., Zhang X.H., et al. Roles of NMDA NR2B subtype receptor in prefrontal long-term potentiation and contextual fear memory. Neuron 2005, 47:859-872.
52. Carroll J.C., Boyce-Rustay J.M., Millstein R., Yang R., Wiedholz L.M., Murphy D.L., et al. Effects of Mild Early Life Stress on Abnormal Emotion-related Behaviors in 5-HTT Knockout Mice. Behav Genet 2007, 37:214-222.
53. Ihne J.L., Fitzgerald P.J., Hefner K.R., Holmes A. Pharmacological modulation of stress-induced behavioral changes in the light/dark exploration test in male C57BL/6J mice. Neuropharmacology 2012, 62:464-473.
54. Carlen M., Meletis K., Siegle J.H., Cardin J.A., Futai K., Vierling-Claassen D., et al. A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Mol Psychiatry 2012, 17:537-548.
55. Engin E., Treit D., Dickson C.T. Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models. Neuroscience 2009, 161:359-369.
56. Haller J., Nagy R., Toth M., Pelczer K.G., Mikics E. NR2B subunit-specific NMDA antagonist Ro25-6981 inhibits the expression of conditioned fear: a comparison with the NMDA antagonist MK-801 and fluoxetine. Behav Pharmacol 2011, 22:113-121.
57. Mathur P., Graybeal C., Feyder M., Davis M.I., Holmes A. Fear memory impairing effects of systemic treatment with the NMDA NR2B subunit antagonist, Ro 25-6981, in mice: Attenuation with ageing. Pharmacol Biochem Behav 2009, 91:453-460.
58. Doucet M.V., Levine H., Dev K.K., Harkin A. Small-molecule inhibitors at the PSD-95/nNOS interface have antidepressant-like properties in mice. Neuropsychopharmacology 2013, 38:1575-1584.